Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Eli Lilly

INDIANAPOLIS , May 20, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for OLUMIANT® (baricitinib) for the treatment of adults with severe alopecia areata (AA). This opinion marks the first step toward European regulatory approval of OLUMIANT for patients with severe AA, and it is now referred to the European Commission for final action.

CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)

Eli Lilly & Co. LLY, -1.22% and Incyte INCY, +4.80% said Wednesday the Food and Drug Administration has approved the use of their Olumiant for the treatment of certain adults who are hospitalized with COVID-19. The treatment, also called baricitinib, will be used for patients who require oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days or until hospital discharge, whichever comes first.

FDA approves Eli Lilly and Incyte's Olumiant for treatment of certain hospitalized adults with COVID-19

OLUMIANT is the first and only JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support INDIANAPOLIS , May 11, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days or until hospital discharge, whichever comes first. "More than two years into the pandemic, COVID-19 is still hospitalizing many people and burdening our healthcare system.

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces European Commission Approval of Jakavi (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic GVHD.

Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

Incyte Corporation's (NASDAQ: INCY) Q1 adjusted EPS reached $0.55, compared to $0.67 posted a year ago. Analysts had estimated $0.68.

Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance

Incyte's (INCY) earnings and revenues miss estimates in the first quarter of 2022. The company raises the bottom end of full-year Jakafi net product revenue guidance.

Incyte's (INCY) Q1 Earnings and Revenues Fall Shy of Estimates

Incyte Corporation (NASDAQ:INCY ) Q1 2022 Earnings Conference Call May 3, 2022 8:00 AM ET Company Participants Christine Chiou – Head-Investor Relations Hervé Hoppenot – Chairman, President and Chief Executive Officer Barry Flannelly – Executive Vice President and General Manager-North America Steven Stein – Executive Vice President and Chief Medical Officer Christiana Stamoulis – Executive Vice President and Chief Financial Officer Conference Call Participants Vikram Purohit – Morgan Stanley Kripa Devarakonda – Truist Securities Matthew Phipps – William Blair Mara Goldstein – Mizuho Marc Frahm – Cowen and Company Leon Wang – Bank of America Operator Hello and welcome to the Incyte First Quarter 2022 Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Incyte's (INCY) CEO Hervé Hoppenot on Q1 2022 Results - Earnings Call Transcript

Incyte (INCY) delivered earnings and revenue surprises of -3.51% and 4%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Incyte (INCY) Lags Q1 Earnings and Revenue Estimates

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs.

Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Biogen

Esperion Therapeutics

Pfizer

Teva Pharmaceutical

Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.

Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More

Novo Nordisk

Seagen

Which biotech stocks do you have on your May 2022 watchlist?

3 Top Biotech Stocks To Watch In May 2022

First Trust Nasdaq Semiconductor ETF

Roku

These are the best Nasdaq stocks to invest in now. INCY, ROKU and FTXL can make great investments in the rest of the year.

3 Nasdaq Stocks to Buy Now for Growth

WILMINGTON, Del. & OSAKA, Japan--(BUSINESS WIRE)---- $INCY--Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan

Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan

Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Incyte (INCY) Q1 Earnings Expected to Decline

Amgen

Corcept Therapeutics

Harmony Biosciences Holdings

Regeneron Pharmaceuticals

Bio-Techne

Biotech stocks were some of the best performers at the start of the pandemic. More recently, though, they've vastly underperformed the broader market.

7 Best Biotech Stocks to Build Your Portfolio

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer

Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer

Jakafi (ruxolitinib) sales were up 15% y/y and the label is expanding. Olumiant is ramping up royalties.

Incyte Is A Buy As Ruxolitinib Ramps Revenue And Pipeline Matures

New England Journal of Medicine published OLUMIANT 36-week alopecia areata data today INDIANAPOLIS, March 26, 2022 /PRNewswire/ -- Adults with severe alopecia areata (AA) who took OLUMIANT® (baricitinib) achieved significant scalp, eyelash and eyebrow hair regrowth and nearly 75% of those who responded to OLUMIANT 4-mg achieved 90% scalp coverage at 52 weeks, Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today at the American Academy of Dermatology (AAD) Annual Meeting. In February 2022, the U.S. Food and Drug Administration (FDA) granted priority review for OLUMIANT in severe AA as a potential first-in-disease medicine.

Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #aad2022--Incyte Announces 52-Week Data from the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients with Vitiligo

Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease

Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease

Incyte: All Atention On Opzelura

The recent pipeline setbacks will weigh on Incyte's (INCY) growth trajectory and jeopardize its plans to diversify its revenue base.

Incyte's (INCY) Going Gets Tough Due to Pipeline Setbacks

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2022--Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming American Academy of Dermatology (AAD) Annual Meeting, held March 25-29, 2022, in Boston. New 52-week data from the Phase 3 TRuE-V vitiligo program evaluating the safety and efficacy of ruxolitinib cream in adolescent and adult patients (age ≥12 years) with vitiligo will be presented as an oral presentation in a late-break

Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting

Incyte' s (INCY) sNDA seeking label expansion of ruxolitinib cream gets extended by three months by the FDA for reviewing additional information.

Incyte (INCY) Label Expansion for Ruxolitinib Cream Delayed

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for Vitiligo

Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo

News for Incyte Stock (INCY)